Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives

Current Medical Research and Opinion

Volumn 30, Issue 11, 2014, Pages 2389-2396

  Koopmans, Gineke ^a   Simpson, Karen ^b   De Andrés, Javier ^c   Lux, Eberhard Albert ^d   Wagemans, Michel ^e   Van Megen, Yvonne ^a  

^a Mundipharma Pharmaceuticals BV   (Netherlands)

^b Glebe House   (United Kingdom)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d St Marien Hospital Lunen   (Germany)

^e REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

Chronic pain; Constipation; Laxatives; Naloxone; Opioid analgesic; Oxycodone

Indexed keywords

BISACODYL; EMOLLIENT AGENT; ENEMA; LAXATIVE; NALOXONE PLUS OXYCODONE; OPIATE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYCODONE NALOXONE COMBINATION;

ADULT; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CANCER PAIN; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPIOID INDUCED CONSTIPATION; OUTCOME ASSESSMENT; PAIN SEVERITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROLONGED DRUG RELEASE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING; AGED; CHEMICALLY INDUCED; CHRONIC PAIN; CLINICAL TRIAL; COMPLICATION; DEFECATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; DEFECATION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; LAXATIVES; MALE; MIDDLE AGED; NALOXONE; NEOPLASMS; OXYCODONE; TREATMENT OUTCOME;

EID: 84908608790     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.971355     Document Type: Article

References (43)

1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on Daily life, and treatment. Eur J Pain 2006;10:287-333
2. Strine TW, Hootman JM, Chapman DP, et al. Health-related quality of life, health risk behaviors, and disability among adults with pain-related activity difficulty. Am J Public Health 2005;95:2042-8
3. Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest 2005;23:182-90
4. van Den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007;132:312-20
5. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
6. Leppert W. Pain management in patients with cancer: focus on opioid analgesics. Curr Pain Headache Rep 2011;15:271-9
7. Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii139-54
8. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
9. Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72:1847-65
10. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009;5:145-51
11. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009;155:11-17
12. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
13. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42
14. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008;27:1224-32
15. Abramowitz L, Beziaud N, Labreze L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ 2013;16:1423-33
16. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009;5:137-44
17. Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care 2010;19:44-51
18. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - guidance. Pain Physician 2012;15(3 Suppl):S67-116
19. Ahmedzai SH, Boland J. Constipation in people prescribed opioids. Clin Evid (Online) 2010;04:2407
20. Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011;(1):CD003448
21. Roerig JL, Steffen KJ, Mitchell JE, Zunker C. Laxative abuse: epidemiology, diagnosis and management. Drugs 2010;70:1487-503
22. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage 2008;35:103-13
23. Tack J, Muller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation - A European perspective. Neurogastroenterol Motil 2011;23:697-710
24. Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40:696-703
25. Citron ML, Kaplan R, Parris WC, et al. Long-Term administration of controlledrelease oxycodone tablets for the treatment of cancer pain. Cancer Invest 1998;16:562-71
26. Ferrarese F, Becchimanzi G, Bernardo M, et al. Pain treatment with highdose, controlled-release oxycodone: an Italian perspective. Ther Clin Risk Manag 2008;4:665-72
27. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7
28. Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011;20:427-39
29. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, activecontrolled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60
30. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-To-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
31. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/ severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
32. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/ naloxone compared with oxycodone alone for the relief of opioidinduced constipation in moderate-To-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
33. van Dongen VC, Vanelderen PJ, Koopmans-Klein G, et al. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study]. Int J Clin Pract 2014 May 23
34. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-Term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74
35. Amedzai SH, Leppert W, Janecki M, et al. Long-Term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-To- severe chronic cancer pain. Support Care Cancer 2014 Sep 14. [Epub ahead of print
36. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. Expert Opin Pharmacother 2012;13:299-311
37. Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
38. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371-83
39. Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011;39:41-50
40. Fallon M. Constipation in cancer patients: prevalence, pathogenesis and costrelated issues. Eur J Pain 1999;3(Suppl 1):3-7
41. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006;14:890-900
42. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
43. Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22:161-6